Moderna to acquire OriCiro Genomics for $85M

Moderna and OriCiro Genomics K.K., a pioneer in cell-free DNA synthesis and amplification technologies, announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85M. "With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing," said Stephane Bancel, CEO of Moderna. "OriCiro’s technology strategically complements our manufacturing expertise and further accelerates our research and development engine. We look forward to welcoming the OriCiro team to Moderna."